RhuFab V2 safety and benefits maintained with continued dosing

May 5, 2003

Ft. Lauderdale-New results from the ongoing, Phase Ib/II open-label,randomized controlled trial of rhuFab V2 for the treatment of exudativeAMD show that a second course of treatment with up to four injection iswell-tolerated and provides ongoing biologic activity, reported JeffreyS. Heier, MD.